Why Did Novartis/1A Pharma Withdraw Its Paracetamol Liquid From The German Market?
HBW Insight chats with general manager of Novartis' German subsidiary 1A Pharma about the firm's exit from the country's children's fever category. An inflexible price system for reimbursable medicines and inflationary pressures all contributed to the decision, Michael Klein explains, which has left only two manufacturers supplying the OTC liquid paracetamol market.
You may also be interested in...
Germany’s Bundesministerium für Gesundheit is reworking the country’s off-patent drug legislation to allow for more flexible pricing.
There are no OTC analgesic supply issues in UK despite higher than normal demand, says consumer heathcare industry association PAGB in response to what it labels “partial and incomplete reporting” in the country's media. HBW Insight looks at NielsenIQ market data for the week ending 7 Janurary to get behind the headlines.
The latest German consumer healthcare launches: Sanofi adds bilastine antihistamine to Allegra range; Teva's Ratiopharm delivers paracetamol and ibuprofen combo thanks to Rx-to-OTC switch; and P&G livens up WICK ZzzQuil sleep aid gummies with tropical fruit flavour.